A
11.39
-0.03 (-0.26%)
| Penutupan Terdahulu | 11.42 |
| Buka | 11.37 |
| Jumlah Dagangan | 2,052,723 |
| Purata Dagangan (3B) | 1,566,329 |
| Modal Pasaran | 1,250,844,928 |
| Harga / Jualan (P/S) | 0.660 |
| Harga / Buku (P/B) | 5.60 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | 16,317.06% |
| EPS Cair (TTM) | -3.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -99.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.69% |
| Nisbah Semasa (MRQ) | 12.05 |
| Aliran Tunai Operasi (OCF TTM) | -206.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -182.62 M |
| Pulangan Atas Aset (ROA TTM) | -40.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -83.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Menaik | |
| Stok | Amylyx Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.30 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 9.54% |
| % Dimiliki oleh Institusi | 85.89% |
| Julat 52 Minggu | ||
| Median | 20.00 (75.59%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2025 | 20.00 (75.59%) | Beli | 12.31 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| COHEN JOSHUA B | - | 13.91 | -138,167 | -1,869,558 |
| KLEE JUSTIN B. | - | 13.91 | -138,188 | -1,869,858 |
| MILNE GEORGE M JR | - | 12.39 | -17,780 | -220,294 |
| Jumlah Keseluruhan Kuantiti Bersih | -294,135 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,959,710 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 13.61 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KLEE JUSTIN B. | Pegawai | 16 Jan 2026 | Jual (-) | 1,995 | 14.30 | 28,529 |
| KLEE JUSTIN B. | Pegawai | 16 Jan 2026 | Pelaksanaan pilihan | 2,847 | - | - |
| COHEN JOSHUA B | Pegawai | 16 Jan 2026 | Jual (-) | 1,974 | 14.30 | 28,228 |
| COHEN JOSHUA B | Pegawai | 16 Jan 2026 | Pelaksanaan pilihan | 2,818 | - | - |
| KLEE JUSTIN B. | Pegawai | 15 Jan 2026 | Jual (-) | 136,193 | 13.52 | 1,841,329 |
| KLEE JUSTIN B. | Pegawai | 15 Jan 2026 | Pelaksanaan pilihan | 197,153 | - | - |
| COHEN JOSHUA B | Pegawai | 15 Jan 2026 | Jual (-) | 136,193 | 13.52 | 1,841,329 |
| COHEN JOSHUA B | Pegawai | 15 Jan 2026 | Pelaksanaan pilihan | 197,182 | - | - |
| MILNE GEORGE M JR | Pengarah | 12 Jan 2026 | Dibuang (-) | 17,780 | 12.39 | 220,294 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S |
| 05 Dec 2025 | Pengumuman | Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial |
| 06 Nov 2025 | Pengumuman | Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences |
| 30 Oct 2025 | Pengumuman | Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |